Capital Allocation 2026: Balancing R&D Spend with Market Access

Capital Allocation 2026: Balancing R&D Spend with Market Access for Medical Industry is not simply a finance question. It is a product strategy, regulatory, reimbursement, and leadership question. A #MedicalProduct can meet its technical milestones and still struggle to reach patients if the company has not funded the evidence, coding, payment, contracting, implementation, and commercial capabilities needed for adoption.

For executives, the central issue is not whether to invest in innovation. It is whether each investment has a credible path from R&D to reimbursed, usable care. We recommend treating market access as a capital-allocation requirement early in product planning, not as a late commercial task after regulatory approval.

Table Of Contents

  1. Key Takeaways
  2. Treat Market Access As A Development Gate
  3. Build An Evidence Adjusted Capital Model
  4. Sequence Portfolio And Talent Decisions
  5. Capital Allocation Questions Executives Ask
  6. Resources And Citations

Key Takeaways

• FDA clearance or approval and commercial market access are separate milestones with separate capital needs.

• There is no credible universal percentage split between R&D and market-access spending. Funding should be set at the product, indication, customer, and reimbursement-pathway level.

• Evidence budgets should cover clinical data, health economics and outcomes research, real-world evidence, coding, coverage, payment, contracting, and implementation where relevant.

• Risk-adjusted NPV models should include reimbursement downside cases, including delayed coverage, restricted access, lower payment, price pressure, and slower provider adoption.

• Executive teams need leaders who can connect product development, regulatory strategy, clinical evidence, payer needs, and commercialization decisions before late-stage spending becomes difficult to reverse.

Treat Market Access As A Development Gate

Approval Is Necessary, But It Does Not Create Demand

FDA authorization answers a regulatory question: whether a drug, device, diagnostic, or #DigitalMedical product may enter the market under its applicable pathway. It does not automatically establish coding, coverage, payment, formulary placement, hospital purchasing approval, provider workflow fit, or patient affordability.

That distinction matters because revenue assumptions can fail after a technically successful development program. A device may receive clearance yet lack a workable payment pathway. A diagnostic may show analytical performance but not demonstrate enough clinical utility for payer coverage. A drug may gain approval but face access restrictions, prior authorization, step therapy, or long contracting cycles.

Deloitte’s midyear outlook reported that R&D was the largest investment area for life sciences organizations in 2026, reflecting pipeline renewal, product development, and evidence generation. The same finding should not be read as a reason to protect R&D spending in isolation. It is a reason to ask whether R&D plans include the evidence needed to support commercial access. See Deloitte’s finding that R&D remains the largest reported investment area.

Make Access Readiness A Formal Stage Gate

A practical stage gate should occur before a company commits to expensive late-stage trials, pivotal studies, scaled manufacturing, or full commercial buildout. The gate asks whether the asset has a plausible access thesis, not merely a plausible regulatory thesis.

At minimum, the decision should test five questions:

  1. Who is the economic buyer? The user, prescribing clinician, hospital, payer, health system, distributor, and patient may have different incentives.
  2. What evidence changes the buyer’s decision? Technical performance alone may not be enough. Comparative outcomes, workflow savings, avoided admissions, or total-cost impact may matter more.
  3. What is the reimbursement route? The answer may involve existing coding, a new code, a coverage determination, facility payment, physician payment, procurement budgets, or direct purchase.
  4. What is the expected time to usable access? Approval-to-revenue timing should be modeled separately from trial completion and regulatory review.
  5. What must the company fund after approval? Contracting, medical affairs, field reimbursement, provider training, clinical implementation, data collection, and patient support can all be material costs.

Consider an AI-enabled diagnostic intended for hospital use. The technical team may prioritize model accuracy and regulatory validation. The access team may need evidence that the tool changes clinical decisions, fits imaging or #LaboratoryWorkflows, and reduces downstream costs. If that evidence is absent, the company may still gain market entry, but adoption can be slow and dependent on local budget exceptions. That is not an R&D failure. It is an access-planning failure.

Fund The Capability, Not Only The Asset

Medical Device Innovation increasingly depends on cross-functional execution. This is especially true in Medical Device AI, Medical Device Robotics, cybersecurity-enabled devices, and products requiring ongoing clinical data collection. The product must be supported by the people and operating systems that make its value credible to buyers.

Executives should separate innovation spend from access-enabling spend in board reporting. Innovation spend includes discovery, engineering, preclinical work, clinical development, and regulatory activities. Access-enabling spend includes HEOR, payer research, coding analysis, clinical education, evidence dissemination, implementation support, contracting, and post-market evidence.

The separation does not mean treating these budgets as competitors. It means making the trade-off visible. If an organization spends heavily to reach approval but underfunds the work required to obtain coverage and provider adoption, it may create a cash-flow gap precisely when launch costs increase.

For medical-device businesses, Strengthening your medical device supply chain should also be considered part of commercialization readiness. A reimbursement win has limited value if manufacturing, quality, supplier continuity, or distribution cannot support reliable delivery.

Build An Evidence Adjusted Capital Model

Replace Corporate Percentages With Product-Level Budgets

Executives often ask what percentage of capital should go to R&D versus commercialization. No standard percentage can answer that responsibly. A pre-revenue diagnostic pursuing new reimbursement may need a larger share of its budget for clinical utility and payer evidence than an established device extension using existing payment channels. A specialty drug with a complex access environment may require significant medical affairs and contracting investment before broad uptake is realistic.

The better unit of analysis is the asset-indication-market combination. One platform may have very different economics across indications, care settings, and payer mixes.

Capital CategoryCore QuestionWhen Spending Should IncreaseWarning Sign
Technical R&DCan the product perform reliably and safely?Product risk remains the main barrierMore features are funded while buyer value remains unclear
Clinical EvidenceDoes the product improve meaningful outcomes?Payers or providers need comparative dataStudy endpoints do not address purchaser concerns
Regulatory WorkWhat evidence is required for authorization?Pathway complexity or submission risk is highRegulatory plans are mistaken for access plans
HEOR And RWECan the company demonstrate economic and real-world value?Payment, utilization, or budget impact is contestedEconomic claims lack usable data
Access And ContractingCan customers obtain and pay for the product?Coding, coverage, pricing, or contracting are uncertainLaunch assumptions depend on untested payment assumptions
ImplementationCan providers adopt the product in routine care?Workflow, training, integration, or cybersecurity requirements are materialSales forecasts ignore operational friction

This approach also improves portfolio prioritization. An asset with a smaller technical upside but a fast reimbursement route may create more near-term value than a scientifically impressive program that requires years of additional evidence and #MarketDevelopment.

Add Reimbursement Risk To Risk Adjusted NPV

Traditional risk-adjusted NPV models usually account for technical and regulatory probabilities. They should also include the probability and timing of commercially usable access.

A practical model includes at least four probabilities:

  1. Technical success: Can the product meet its intended performance profile?
  2. Regulatory success: Can it receive the needed FDA authorization or approval?
  3. Access success: Can it gain sufficient coding, coverage, payment, pricing, and contracting support?
  4. Adoption success: Will providers, health systems, and patients use it at the expected rate?

The downside case should be explicit. For example, a base case may assume coverage within 12 months of approval. A downside case could assume 24 months, restricted population criteria, lower payment, and additional post-market evidence requirements. The financial result may change enough to alter the decision to self-fund, partner, license, delay, or stop development.

Deloitte found that 29% of biopharma leaders and 37% of medtech leaders identified pricing, access, contracting, and reimbursement as key focus areas for 2026. That level of leadership attention supports treating access as a board-level financial issue rather than an isolated commercial function. The underlying survey result is available in Deloitte’s 2026 life sciences outlook on pricing, access, contracting, and reimbursement.

Stress Test Timing, Not Just Value

Cash needs often rise before revenue arrives. A trial delay, FDA information request, slower-than-expected coverage decision, or longer contracting cycle can create a financing problem even when the asset remains valuable on paper.

A 2026 stress test should model:

• A delayed pivotal study or additional clinical-data request.

• Slower enrollment, site activation, or manufacturing scale-up.

• Six to 18 months of delayed coverage or coding progress.

• Lower payment or tighter utilization management than the base case assumes.

• A need for additional post-market evidence to support provider or payer adoption.

• A financing round, strategic partnership, or acquisition process taking longer than planned.

Smaller companies should be particularly disciplined here. Constrained capital can suppress medtech R&D and affect clinical trials and device approvals. The right response is not always to spend less. It may be to narrow the indication, redesign the evidence plan, seek a strategic partner, or focus first on a customer segment with clearer payment and implementation conditions.

Pharma industry leaders focus on risk management is relevant because #CapitalPlans are strongest when risk management is built into portfolio decisions rather than added after budgets have been approved.

Sequence Portfolio And Talent Decisions

Choose Markets By Evidence Readiness And Reimbursement Speed

Market sequencing should not be treated as a geographic expansion checklist. It is a capital allocation choice about where the next dollar creates the strongest probability-adjusted return.

For U.S. companies, the first market may not always be the largest possible population. It may be the segment where clinical evidence is strongest, buyer incentives are clearest, and reimbursement is fastest. A focused launch can create real-world evidence, reference customers, and revenue that fund broader expansion.

This is particularly relevant for Medical Device International Expansion. A product that can enter one market quickly may still require separate clinical, regulatory, payment, language, distribution, data-security, and procurement preparation elsewhere. International expansion should therefore have its own capital model rather than being assumed to follow automatically after U.S. authorization.

For example, a robotic surgical platform may have strong physician interest but require capital equipment approvals, service infrastructure, training, hospital value-analysis review, and procedure-level payment support. A narrower launch to health systems with existing infrastructure may be financially wiser than a broad rollout that spreads field resources too thin.

Compare Internal R&D, Licensing, And Acquisition On Evidence Risk

Internal R&D, licensing, and acquisition are not interchangeable routes to growth. Each has a different capital profile.

OptionPrimary AdvantageMain RiskBest Fit
Internal DevelopmentGreater control over product design and evidence strategyLong time to proof and high execution burdenStrong internal scientific, regulatory, and commercial capabilities
LicensingFaster access to an external asset or technologyInherited evidence gaps, royalties, and integration complexityA company can add access or development value quickly
AcquisitionCan add products, capabilities, teams, or channelsValuation, integration, and hidden access liabilitiesA clear portfolio gap exists and the organization can integrate effectively

The comparison should focus on evidence-adjusted risk, not just purchase price or development cost. An acquired product may have regulatory authorization but weak payment support. A licensed technology may reduce discovery risk but require #SubstantialInvestment in clinical validation and reimbursement. Internal development may be slower, yet it can allow evidence planning to align with the intended market from the beginning.

This is where Medical Device Strategic Partnerships can be valuable. A partnership may provide trial infrastructure, distribution access, data, manufacturing capacity, or commercial reach without requiring a full acquisition. It is not automatically cheaper, but it can reduce timing risk when the partner contributes a capability the company would otherwise need to build.

Leadership Is A Capital Allocation Variable

A capital plan can fail if the leadership team is organized around functional handoffs rather than integrated decisions. Many medical companies need executives who can translate between product, clinical, regulatory, finance, reimbursement, quality, and commercial teams.

The leadership requirements are becoming more specific. A general commercial executive may not be equipped to lead a launch dependent on Medical Device Clinical Data, value-based contracting, health-system implementation, or #MedicalDeviceCybersecurity review. Likewise, a technically strong R&D leader may not have the mandate or background to redesign development plans around payer evidence.

We suggest evaluating executive roles against the decisions they must make, not only against past titles. For a chief product, clinical, regulatory, market-access, or commercial leader, assess whether the candidate can:

• Challenge trial endpoints that do not support buyer decisions.

• Explain the difference between FDA authorization and reimbursement readiness.

• Build an evidence plan across regulatory, clinical, economic, and real-world needs.

• Prioritize indications when capital cannot support every opportunity.

• Coordinate Medical Device Regulatory, quality, cybersecurity, and commercialization requirements.

• Lead a partner, payer, provider, or investor conversation without overstating certainty.

A prolonged vacancy in one of these roles can delay decisions that are difficult to recover later. For example, if a market-access leader joins after pivotal-study design is fixed, the company may need a separate evidence program to answer payer questions that could have been addressed earlier. The cost is not only salary or recruitment expense. It can be delayed launch timing and a weaker commercial case.

For organizations reviewing pipeline efficiency and leadership needs together, R&D efficiency strategies driving pharma innovation offers related context on aligning development choices with growth priorities.

Capital Allocation Questions Executives Ask

How Should A Medical Company Balance R&D And Market Access Spending In 2026?

Start with the product’s access barriers, not a fixed corporate percentage. Fund the technical, clinical, regulatory, economic, and operational evidence required for the intended buyer to adopt the product. If payment is uncertain, access-enabling spend should rise before late-stage R&D commitments become irreversible.

Should Market Access Planning Begin Before Clinical Trials?

Yes. Market access planning should inform trial design, endpoint selection, comparator choices, patient population, economic measures, and evidence-generation plans. Waiting until after approval can leave a company with regulatory data that does not answer payer or provider questions.

What Is The Difference Between FDA Approval And Commercial Market Access?

FDA approval or clearance allows a product to be marketed under the applicable regulatory framework. Commercial market access includes the conditions that make use feasible: coverage, coding, payment, pricing, contracting, distribution, workflow adoption, and patient affordability. A product may have one without the other.

How Should Reimbursement Risk Be Included In An R&D Business Case?

Model reimbursement as a separate probability and timing assumption. Include downside cases for delayed coverage, restricted populations, lower payment, payer evidence requests, and slower provider adoption. Then compare the revised risk-adjusted NPV with alternatives such as partnering, licensing, narrowing the indication, or pausing investment.

What Evidence Do Payers And Health Systems Need?

Requirements vary by product type, care setting, patient population, and payer. In general, decision-makers may assess clinical benefit, comparative effectiveness, safety, budget impact, total cost of care, workflow impact, and the strength of real-world evidence. Companies should validate these needs early rather than assume a regulatory package will be sufficient.

When Does HEOR Spending Create Enough Value?

HEOR is most useful when it addresses a decision that can change coverage, payment, formulary status, purchasing, contracting, or adoption. It is less useful when it produces broad claims without a direct link to the buyer’s criteria. For example, an #EconomicModel may be valuable if it shows avoided hospitalizations in a defined high-risk population, but weak if it rests on assumptions that purchasers cannot validate.

How Should Smaller Medtech Companies Prioritize Indications?

Prioritize the indication with the strongest combination of unmet need, evidence feasibility, reimbursement pathway, implementation fit, and capital efficiency. The largest theoretical market is not always the best first market. A smaller segment with clearer payment and faster adoption can create the evidence and revenue needed for later expansion.

Resources And Citations

• Deloitte.com. https://www.deloitte.com/us/en/insights/industry/health-care/midyear-2026-life-sciences-outlook.html

• Deloitte.com. https://www.deloitte.com/content/dam/assets-zone2/it/it/docs/industries/life-sciences-health-care/2026/2026_Life-Sciences-Outlook_Deloitte.pdf

• BrightPath Associates: Strengthening your medical device supply chain

Find your next leadership role in Medical Device Industry today!

Stay informed with the latest insights on Medical Device Industry!

Discover more about our staffing and recruitment solutions!